IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines. Checkpoint/cancer vaccines suppress the function of regulatory immune cells and induce inflammation in the microenvironment in addition to direct targeting of cancer cells.

Overview

Total FundingEmployeesLast Funding DateStatus
$11,908,7572016-01-05Operating

Crunchbase Investment Rounds

DateAmountRoundValuationLead InvestorOther Investors
2016-01-05$11,908,757VentureLundbeckfonden VenturesNovo Nordisk